Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 20Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Colorectal Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Brain Neoplasms 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urethral Neoplasms 1

Interventions

relacorilant 2Mifepristone 2Corlux 2tariquidar 1pembrolizumab 1cabozantinib 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Gefitinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adrenal Cortex Neoplasms × cabozantinib × Clear all
NCT03370718 2024-12-10

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 5 charts

Adrenal Cortex Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡